Altimmune Inc. (ALT)

LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) ("ALT5 or the "Company"), a fintech company providing blockchain-powered payment and trading infrastruct...

On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

Despite Altimmune, Inc.'s sharp selloff, I believe the market overreacted to pemvidutide's Phase IIb MASH data, which showed meaningful liver improvements and strong safety. The modest weight loss in ...

Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely ...

Shares of Altimmune Inc (NASDAQ:ALT) tumbled 55% on Thursday after the company reported mixed results from a mid-stage trial of its experimental drug pemvidutide for metabolic dysfunction-associated s...

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease.

Eli Lilly (LLY -0.41%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients w...

LAS VEGAS, NV / ACCESS Newswire / June 11, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech specializing in turnkey, crypto-related solutions for institutions and merchants, is pleased...

I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in ...